Pursuant to Regulation 30 read with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (LODR), Eris Lifesciences has informed that the Board of Directors of the Company, in their meeting held today, i.e., July 29, 2026, duly approved and took on record the following: 1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. In this regard, the following documents are enclosed: A copy of the said financial results along with Limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications); Details as per Regulation 52(4) of SEBI Listing Regulations; and 2. Re-appointment of Kiran J. Mehta & Co., Cost Accountants, as the Cost Auditors of the Company for the financial year 2026-27. The details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. H0/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026, are given in the Annexure. The meeting of the Board of Directors commenced at 11:30 AM and concluded at 01:00 PM.
The above information is a part of company’s filings submitted to BSE.
